Csl Limited · ASX:CSL
Csl — Shareholder Meeting (October 2024)
39 slides from Csl's shareholder meeting presentation, Oct 29, 2024
Slide 1: CSL Limited Annual General Meeting 2024
For immediate release 29 October 2024 CSL LIMITED ANNUAL GENERAL MEETING 2024 For personal use only Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY) Please find attached the Chair and Chief Executive Officer addresses to shareholders ahead of CSL Limited’s Annual General Meeting, which will be held
Slide 2: Chair Address at the 2024 CSL Annual General Meeting
Chair Address at the 2024 CSL Annual General Meeting Good morning, Ladies and Gentlemen. Thank you for joining us today. There is a quorum present and I am delighted to open the meeting. I would now like to introduce your Board of Directors and our Company Secretary. To my right: • Ms Fiona Mead, ou
Slide 3: For personal use only
Today I want to provide a short commentary on your company. Firstly though, a reminder about who we are. CSL is an established global leader in plasma-derived therapies, influenza vaccines and iron therapies. We operate globally in large and growing markets, and we deliver innovative life-saving med
Slide 4: For personal use only
Whilst we are now entering a period of less capital-intensive growth, we will continue to grow as demand for our products increases, and we may need to add further capacity to our network before the end of the decade. The other side of this equation is capability. Specifically, we need the right peo
Slide 5: For personal use only
While we are on the subject of capability, I want to discuss our approach to remuneration, as it is aligned to who we are and what we do as a unique ASX-listed company. Although our heritage is proudly Australian, the global biotechnology sector, and many of our executives are based in the United St
Slide 6: For personal use only
We are dedicated to better serving these people. Sometimes, it works out. Hearing the testimonials from patients dosed with HEMGENIX - our gene therapy for those suffering from Hemophilia B - attests to this. However, there is inherent risk with any investment we make, and at times, things don’t wor
Slide 7: CEO and Managing Director Address at the 2024 CSL AGM
CEO and Managing Director Address at the 2024 CSL Annual General Meeting Thank you, Brian and good morning everyone. I travel to Melbourne several times throughout the year and it truly is my ‘home away from home’. This is my favourite time of year to come here though: the weather is starting to tur
Slide 8: For personal use only
• Developing innovative products is at the very core of why we exist, so we are committed to advancing our R&D pipeline, which I will speak about shortly. As you can see, we’ve made significant progress on the strategic priorities outlined at our Capital Markets Day. This is a testament to the hard
Slide 9: For personal use only
We continue to expand the geographic footprint of our plasma center network, having opened three in Puerto Rico. CSL Seqirus delivered solid sales growth, outperforming the market in a challenging season. Growth was primarily driven by our differentiated portfolio and led by our adjuvanted FLUAD pro
Slide 10: A few highlights from FY24
A few highlights from FY24: In CSL Behring • GARADACIMAB provides a great example of our innovative approach as we aim to build on our ongoing strength in HAE. We are working towards approval in multiple markets before the end of this financial year; • We continue to reinforce our leadership positio
Slide 11: For personal use only
• We will progress to full deployment of the Rika technology, including I-Nomogram. • Horizon 1 and 2 yield initiatives will continue to advance, and • All these factors will drive the expansion of CSL Behring’s gross margin. For CSL Seqirus, we expect: • Continued market outperformance, driven by i
Slide 12: Welcome to CSL's 2024 Annual General Meeting
For personal use only Welcome to CSL’s Driven by Our Promise 2024 Annual General Meeting Please ensure your mobile is on silent mode
Slide 13: Welcome to CSL's 2024 AGM
For personal use only Welcome to CSL’s 2024 AGM Fiona Mead Company Secretary 2
Slide 14: Online attendees – Online text questions
Online attendees – Online text questions For personal use only • Select the messaging tab • Type your question in the ‘Ask a question’ box • Press the arrow symbol to submit your message • Select ‘My Messages’ to view your submitted messages along with any written responses 3
Slide 15: Online attendees – Online audio questions
Online attendees – Online audio questions For personal use only • Click ‘Request to Speak’ • Enter the topic of your question • Click ‘Submit Request’ • Click ‘Join Queue’ and follow the audio prompts 4
Slide 16: Online difficulties
Online difficulties For personal use only If you experience any difficulty with your participation via the online platform, please call +61 2 8075 0100 5
Slide 17: Fiona Mead, Company Secretary
For personal use only Fiona Mead Company Secretary 6
Slide 18: Online attendees – Online voting
Online attendees – Online voting For personal use only • Select the voting tab • Select your voting preference for each resolution • Your selected option will change colour • You can change your vote until the poll is closed 7
Slide 19: Legal Notice
Legal Notice IMPORTANT NOTICE AND DISCLAIMER For personal use only This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL) and CSL's activities as at the date of this presentation. It is information given in summary form onl
Slide 20: Address from the Chair
For personal use only Address from the Chair Brian McNamee AO Chair and Independent Non-Executive Director 9
Slide 21: Board of Directors and Company Secretary
Board of Directors and Company Secretary For personal use only Paul McKenzie Megan Clark AC Andrew Cuthbertson AO Carolyn Hewson AO Samantha Lewis Managing Director Non-executive Director Non-executive Director Non-executive Director Non-executive Director Duncan Maskell Marie McDonald Elaine Sorg A
Slide 22: Address from the Chair
For personal use only Address from the Chair Brian McNamee AO Chair and Independent Non-Executive Director 11
Slide 23: Leading positions in large, growing markets
Leading positions in large, growing markets For personal use only Global #1 Global #2 Global #1 in plasma protein therapies in influenza vaccines in iron therapies ~$38 billion industry ~$7 billion industry ~$5 billion industry US$2.64 US$14.8bn 110 million dividend per share for 2024 in annual reve
Slide 24: Delivering capital-efficient growth
Delivering capital-efficient growth For personal use only US$m % of Revenue 1,400 14% 1,200 12% 1,000 10% 800 8% 600 6% 400 4% 200 2% - 0% FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 Capex % of Rev Capital Expenditure for Property, Plant & Equipment 13
Slide 25: For personal use only
For personal use only
Slide 26: For personal use only
For personal use only
Slide 27: For personal use only
For personal use only
Slide 28: Our Therapeutic Areas and Platforms
Our Therapeutic Areas and Platforms For personal use only 17
Slide 29: Logan's Story
Logan’s Story Logan is juggling the busy life of a college senior while managing his haemophilia B. For personal use only Logan is an active presence on campus, working on dual degrees in Finance and Business Economics. As he prepares to finish his education and enter the business world, Logan is ta
Slide 30: For personal use only
For personal use only
Slide 31: Address from CEO and Managing Director
For personal use only Address from CEO and Managing Director Paul McKenzie CEO and Managing Director 20
Slide 32: Delivered on Strategic Priorities in FY24
Delivered on Strategic Priorities in FY24 For personal use only Strong growth, driven by Ig Differentiated portfolio Drive synergies 14% (lg 20%)1 Market outperformance $100m+ p.a. Rika rollout Yield Initiatives CSL Behring gross margin Geographic Expansion 84 Centres Horizon 1 and 2 120 bps1 H
Slide 33: Strong performance
Strong performance1 Revenue +11% CSL Behring Strong growth across the portfolio especially Ig For personal use only NPATA2,3 +15% • Underlying fundamentals of plasma collection remain strong: NPAT3 +25% • Horizon 1 and 2 yield initiatives progressing to plan • Gross margin recovery on track CSL Seqi
Slide 34: CSL Group Financial highlights
CSL Group Financial highlights For personal use only FY23 FY24 FY24 Change CSL Behring 1 1 US$ Millions Rep Rep at CC % Total Revenue 13,310 14,800 14,744 11% • Ig +20%, HAEGARDA® +12%, ALBUMIN® +12%, IDELVION® +10% Gross Profit5 7,231 8,006 8,030 11% • Gross margin +120 bps at CC GP %5 54.3% 54.1%
Slide 35: Forward-Looking Portfolio Highlights – FY25
Forward-Looking Portfolio Highlights – FY25 For personal use only Abbreviations: AFD – Acquired Fibrinogen Deficiency; aGvHD – Acute Graft versus Host Disease; aTIVc- Adjuvanted Cell-Based Trivalent Influenza Vaccine; aQIV – 24 Adjuvanted Quadrivalent Influenza Vaccine; ESKD – End Stage Kidney Disea
Slide 36: Significant progress made with CSL's Sustainability Strategy
Significant progress made with CSL’s Sustainability Strategy For personal use only Moving to 100% Sustainability strategy refreshed renewable electricity Repositioned with focus on healthier in Australia and Europe communities and healthier environment • All Australian facilities from Jan 2025 • Str
Slide 37: FY25 outlook
FY25 outlook CSL Behring CSL Seqirus For personal use only • Underlying patient demand for Ig • Continued market outperformance in core indications remains strong from differentiated portfolio • Positive reimbursement decisions • sa-mRNA COVID vaccine development support HEMGENIX® growth ‒ Commercia
Slide 38: Notes
Notes (#) Constant currency removes the impact of exchange Summary NPAT attributable to members Summary Revenue rate movements to facilitate comparability of operational of parent entity Reported revenue $14,800m performance for the Group. This is done in three parts: a) Reported net profit after ta
Slide 39: Thank you
For personal use only CSL’s 2024 Thank you Annual General Meeting